0UNL.LSE Nektar Therapeutics
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -18.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0UNL.LSE undervalued?
Graham numberThe Graham number of Nektar Therapeutics cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nektar Therapeutics fundamental analysis
No fundamental analysis for Nektar Therapeutics yet.
Nektar Therapeutics stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; a…
Full company profileNektar Therapeutics financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nektar Therapeutics annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 165M | 308M | 1.19B | 115M | 153M | 102M | 92.1M | 90.1M | 98.4M | 55.2M | 42.0M |
| Gross Profit | 127M | 270M | 1.16B | 85.1M | 124M | 67.2M | 62.9M | 56.4M | 66.5M | 54.2M | 41.7M |
| Operating Income | -113M | -39.0M | 688M | -440M | -380M | -446M | -240M | -264M | -133M | -134M | -160M |
| EBITDA | -97.3M | -42.5M | 697M | -383M | -394M | -433M | -324M | -243M | -86.7M | -133M | -160M |
| Net Income | -154M | -96.7M | 681M | -441M | -444M | -524M | -368M | -276M | -119M | -164M | -171M |
| EPS | -1.10 | -0.62 | 3.78 | -2.52 | -2.49 | -2.86 | -1.97 | -1.45 | -0.58 | -9.73 | -5.17 |
| Balance Sheet | |||||||||||
| Total Assets | 569M | 509M | 2.15B | 1.98B | 1.54B | 1.12B | 711M | 398M | 304M | 280M | 1.10B |
| Total Liabilities | 481M | 421M | 433M | 572M | 461M | 438M | 344M | 267M | 243M | 191M | 192M |
| Shareholders' Equity | 88.1M | 87.8M | 1.72B | 1.41B | 1.08B | 680M | 367M | 131M | 60.7M | 89.8M | 903M |
| Cash & Short-term Investments | 389M | 296M | 1.34B | 1.32B | 1.06B | 734M | 505M | 304M | 255M | 246M | 684M |
| Total Debt | 335M | 321M | 309M | 451M | 351M | 291M | 258M | 230M | 194M | 149M | 136M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -117M | -80.4M | 718M | -329M | -313M | -413M | -304M | -193M | -176M | -209M | -240M |
| Capital Expenditure | 6.39M | 9.68M | 14.2M | 26.3M | 7.26M | 15.0M | 5.68M | 865K | 1.47M | 171K | 224K |
| Free Cash Flow | -123M | -90.1M | 704M | -355M | -321M | -428M | -310M | -193M | -177M | -209M | -240M |
| Ratios | |||||||||||
| ROE | -174.2% | -110.1% | 39.7% | -31.4% | -41.3% | -77.1% | -100.4% | -210.8% | -195.9% | -182.6% | -18.9% |
| ROA | -27.0% | -19.0% | 31.7% | -22.3% | -28.9% | -46.9% | -51.8% | -69.4% | -39.2% | -58.5% | -15.6% |
| Net Profit Margin | -92.8% | -31.4% | 57.1% | -384.5% | -290.6% | -514.0% | -400.0% | -306.3% | -120.9% | -297.1% | -407.4% |
| Debt to Equity | 3.80x | 3.65x | 0.18x | 0.32x | 0.33x | 0.43x | 0.70x | 1.76x | 3.20x | 1.66x | 0.15x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Nektar Therapeutics dividends
Nektar Therapeutics has not paid dividends in the last 9 fiscal years.
Last stock split: 1:15 on Jun 9, 2025.
Who owns Nektar Therapeutics
- Insiders 0.38%
- Institutions 99.62%
- Public & others 0.00%
- Free float 28.3M
Nektar Therapeutics company profile
- Company name
- Nektar Therapeutics
- Ticker
- 0UNL.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 63
- Fiscal year end
- December
- Address
- 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
- Phone
- 415 482 5300
- Website
- nektar.com
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics management
10- Mr. Howard W. RobinCEO, President & Director · born 1953
- Dr. Jonathan Zalevsky Ph.D.Senior VP and Chief Research & Development Officer · born 1975
- Ms. Linda M. Rubinstein M.A.CFO and Principal Financial & Accounting Officer · born 1967
- Mr. Jason BarnardChief Accounting Officer
- Ms. Elizabeth ZhangVP of Legal, Corporate Counsel & Secretary
- Mr. Spilios AsimakopoulosVice President of Commercial Strategy & Marketing
- Mr. Robert BacciChief People Officer and Head of Quality & Facilities
- Ms. Jennifer RuddockChief Business Officer
- Dr. Mary Tagliaferri L.Ac., M.D.Chief Medical Officer · born 1966
- Dr. Ken Franke Ph.D.Senior Vice President of Biologics Process Development & Manufacturing